AG
CRNX icon

Artal Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Artal Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,066,064
Closed -$47.7M – 22
2024
Q2 		$47.7M Sell
1,066,064
-324,413
-23% -$15M 1.22% 11
2024
Q1 		$65.1M Buy
+1,390,477
New +$54.4M 1.66% 9
2019
Q2 		– Sell
-200,000
Closed -$4.55M – 107
2019
Q1 		$4.55M Hold
200,000
– – 0.19% 79
2018
Q4 		$6M Hold
200,000
– – 0.22% 63
2018
Q3 		$5.73M Buy
+200,000
New +$5.94M 0.15% 73

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Artal Group's CRNX Position: Q3 2024 in Review

Artal Group sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2024, closing a stake of 1,066,064 shares — an estimated $47.7M sold.

Artal Group first reported a position in CRNX in Q3 2018 and held it in 5 quarters. The position peaked at $65.1M in Q1 2024. 235 funds tracked by Wall St. Rank hold CRNX as of Q3 2024.

  • Artal Group reported no remaining Crinetics Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 1,066,064 Crinetics Pharmaceuticals shares in Q3 2024, an estimated $47.7M.
  • Artal Group first reported a position in Crinetics Pharmaceuticals in Q3 2018 and held it in 5 quarters.
  • Artal Group's Crinetics Pharmaceuticals position peaked at $65.1M in Q1 2024.
  • 235 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.